



SOPs/Instructions for Authors and templates for ESMO eUpdates

ESMO Guidelines Committee, October 2015, latest revision April 2018

eUpdate

- ✓ An electronic update (eUpdate) will be produced in the following instances:
 - When important breakthroughs need to be rapidly communicated.
 - When only few updates are needed for a CPG instead of producing a revised version.
 - When a Magnitude of Clinical Benefit Scale (ESMO-MCBS) score has been produced for a new therapy or a new indication of existing therapy by the EMA in the context of the relevant CPG.

Production of an eUpdate will be proposed by the Subject Editor (SE) or GLC Steering Committee (GLC-SC) and approved by the GLC-SC.

Drafting of the eUpdate is done by the SE and/or CPG coordinating author, reviewed by both and approved by the GLC-SC (see template below).

When the eUpdate refers to an ESMO-MCBS score of a new therapy/indication, it will be drafted by the Subject Editor +/- the lead author of the CPG, reviewed by the MCBS WG and approved by the GLC-SC and the ESMO President's Council. The need for such an eUpdate should be monitored by the SE, lead author and MCBS Working Group. Such eUpdates should be produced within one month.

The eUpdate will be published online and linked to the Guideline pages on esmo.org and OncologyPRO. It will also be incorporated into the CPG when a revised version is produced.

eUpdate – TITLE (describe content of eUpdate, e.g. Prostate Cancer Treatment Recommendations)

Published: DATE

Authors: ESMO Guidelines Committee

Clinical Practice Guidelines

This update refers to the **CPG title, CPG authors, CPG reference (Annals of Oncology)**.

Section

Title of the CPG section to which the update applies

Text update

Background text describing the reasons for update & data

Recommendation

Guidelines recommendation, including Level of Evidence and Grade of Recommendation

Magnitude of Clinical Benefit Scale (MCBS) table for new therapies/indications in XXX^a

Therapy	Disease setting	Trial	Control	Absolute survival gain	HR (95% CI)	QoL/toxicity	MCBS score ^b
Describe the new therapy	Describe the disease setting. Specify (Neo)adjuvant or Advanced	Name, phase of trial, NCT number	Describe the control arm	Median, in months (state OS, PFS or both)	Median and 95% CI	Improved or Deteriorated or Similar or Not Available	Score X (Form X)

^aEMA approvals since January 2016.

^bESMO-MCBS version 1.1 [2].

CI, confidence interval; EMA, European Medicines Agency; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; QoL, quality of life.

References

Pivotal trial reference.

Cherny NI, Dafni U, Bogaerts J et al. ESMO-Magnitude of Clinical Benefit Scale Version 1.1. *Ann Oncol* 2017; 28: 2340–2366.